Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Correlation between expression of COX-2 and CD105 in squanous cell carcinoma (CROSBI ID 551386)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Lipozenčić, Jasna ; Bukvić Mokos, Zrinjka ; Basta-Juzbašić, Aleksandra Correlation between expression of COX-2 and CD105 in squanous cell carcinoma // Book of Abstracts. 10th International Congress of Dermatology. Prag, 2009. str. 586-x

Podaci o odgovornosti

Lipozenčić, Jasna ; Bukvić Mokos, Zrinjka ; Basta-Juzbašić, Aleksandra

engleski

Correlation between expression of COX-2 and CD105 in squanous cell carcinoma

Cyclooxygenase-2 (COX-2) is inducible form of COX, which is overexpressed in several human epithelial carcinomas, including colorectal cancer, breast cancer, lung cancer and squamous cell carcinoma of the head and neck. COX-2 expression is induced by various inflammatory and mitogenic stimuli, including UVB irradiation. Several studies have shown that COX-2 can induce neoangiogenesis, the important event of in the process of carcinogenesis. Endoglin (CD105) is strongly expressed on tumor endothelial cell, and is considered to be one of the most dependable markers of neoangiogenesis. Cutaneous squamous cell carcinoma (SCC) is one of the most commom skin carcinomas, which is mainly caused by chronic sun exposure. Most SCCs develop from precursor lesions such as actinic keratoses (AK) and Bowen's disease (BD), which are actually considered carcinoma in situ. The aim of this study was to evaluate the expression of COX-2 and neoangiogenesis marker CD105 in SCC, AK and BD ; and to compare the expression of these markers in all examined tumors. The study comprised 30 samples of well-differentiated SCC (Broder's grade 1), 30 samples of AK, 30 samples of BD and 30 samples of normal skin. Immunohistochemically, the expression of COX-2 was detected in 86, 7% of SCC, 76, 7% of AK, 83, 3% of BD, and in only 10% of normal skin samples. Semi-quantitative analysis revealed moderately positive reaction in most of SCC and AK samples (SCC: 46, 7% ; AK: 43, 3%), while most of BD samples were weakly positive (53, 3%). Compared to normal epidermis, all skin tumor samples (SCC, AK, BD) were significantly more likely to be COX-2 immunopositive, but there was no significant difference between COX-2 expression in SCC, AK and BD. Expression of CD105 was significantly increased in all skin tumor samples (SCC, AK, BD) comparing to normal skin, and also in SCC comparing to AK. Concerning the expression of CD105, there was no significant difference between AK and BD, and between BD and SCC. The level of expression of COX-2 correlated with the expression of CD105 in all examined groups. Results of this study indicate that COX-2 expression is an early event in carcinogenesis of SCC. COX-2 may stimulate neovascularization in early stages of SCC development, but also in late stages when other proangiogenic factors may be important, too.

COX-2; CD105; Squamous cell carcinoma

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

586-x.

2009.

objavljeno

Podaci o matičnoj publikaciji

Book of Abstracts. 10th International Congress of Dermatology

Prag:

Podaci o skupu

10th International Congress of Dermatology

poster

20.05.2009-24.05.2009

Prag, Češka Republika

Povezanost rada

Kliničke medicinske znanosti